Featured Publications
NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
Marks A, Antaya R, Balsamo L, Cardinale K, Cheron R, Frumberg D, Gentile V, Habib L, Puthenpura V, Zhang H. NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies. Neuro-Oncology 2022, 24: i129-i129. PMCID: PMC9165028, DOI: 10.1093/neuonc/noac079.469.Peer-Reviewed Original ResearchTuberous sclerosisPediatric patients 2 yearsYale-New Haven Children's HospitalInoperable plexiform neurofibromasPatients 2 yearsOwn side effectsYears of ageNeurofibromatosis type 1Multidisciplinary clinicNeurocutaneous syndromeChildren's HospitalPlexiform neurofibromaNeuro-oncologySide effectsSubspecialty consultationClinicType 1Young adultsSclerosisSyndromeHospitalTherapyAgeTreatmentClinical reasoning
2021
CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
Marks A, Bindra R. CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT. Neuro-Oncology Advances 2021, 3: iv1-iv1. PMCID: PMC8453774, DOI: 10.1093/noajnl/vdab112.002.Peer-Reviewed Original ResearchAdult Brain Tumor ConsortiumAYA populationAYA patientsClinical trialsIDH1/2 mutationsPatients ages 13Years of ageInternational clinical trialsYoung adult populationTemozolomide chemotherapyInitial dosingLack of enrollmentGrade IPsychosocial assessmentPARP inhibitor sensitivityUnique cohortDisease processMost trialsGlioma populationInternational trialTrial developmentAdult populationSpecific trialsPatientsTrialsDual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma
Fomchenko EI, Reeves BC, Sullivan W, Marks AM, Huttner A, Kahle KT, Erson‐Omay E. Dual activating FGFR1 mutations in pediatric pilomyxoid astrocytoma. Molecular Genetics & Genomic Medicine 2021, 9: e1597. PMID: 33448156, PMCID: PMC8077124, DOI: 10.1002/mgg3.1597.Peer-Reviewed Original ResearchConceptsPilomyxoid astrocytomaPediatric patientsVariant allele frequencyHypothalamic/chiasmatic regionPathologic tissue diagnosisTreatment-related morbidityHigh recurrence ratePI3K/mTOR inhibitionYears of ageExome sequencing resultsSimilar time pointsWhole exome sequencing resultsHypothalamic dysfunctionClinical presentationSurgical managementRecurrence rateShorter survivalAggressive subtypeVision lossChiasmatic regionTissue diagnosisPatient tumorsRadiation therapyFGFR inhibitorsFGFR1 mutations
2017
PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS
Bornhorst M, Goecks J, Boue D, Broniscer A, Hwang E, Koschmann C, Marks A, Mody R, Mueller S, Orr B, Packer R, Solomon D, Turner J, Vortmeyer A, Nazarian J, Ho C. PDTM-25. GENETIC SUSCEPTIBILITY AND EVOLUTION OF PEDIATRIC IDH-MUTANT INFILTRATING ASTROCYTOMAS. Neuro-Oncology 2017, 19: vi195-vi195. PMCID: PMC5692642, DOI: 10.1093/neuonc/nox168.789.Peer-Reviewed Original ResearchTP53 mutationsPediatric gliomasGermline mutationsIDH mutationsLow-grade tumorsHigh-grade tumorsLow mutation burdenYears of ageHigh-grade astrocytomasGermline TP53 mutationsMismatch repair genesIDH-mutant astrocytomasYounger patientsMulti-institution studyEarly lesionsMutation burdenMutant allele frequencyPatientsSporadic casesAstrocytomasTumorsSporadic tumorsAdult counterpartsGenetic susceptibilityLow cellularity
2016
Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database
Lucchesi KM, Grant R, Kahle KT, Marks AM, DiLuna ML. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. Journal Of Neuro-Oncology 2016, 130: 133-140. PMID: 27423644, DOI: 10.1007/s11060-016-2218-6.Peer-Reviewed Original ResearchConceptsGross total resectionOverall survivalSpinal myxopapillary ependymomaMyxopapillary ependymomaSubtotal resectionPatient demographicsPediatric patientsEnd Results (SEER) databaseNational Cancer DatabaseKaplan-Meier methodGoal of treatmentYears of ageLargest survival analysisAdjuvant radiationMean followPatients 21SEER databaseSurgical resectionMedian agePediatric populationResults databaseTumor recurrenceCauda equinaTreatment modalitiesCancer Database